| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 5284 |
| clone | 6E5A9 |
| WB Predicted band size | 83.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PIGR (AA: extra 19-170) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于PIGR(多聚免疫球蛋白受体)抗体的参考文献及其简要摘要：
---
1. **文献名称**：*"The polymeric immunoglobulin receptor: Bridging innate and adaptive immune responses at mucosal surfaces"*
**作者**：Kaetzel, C.S. (2005)
**摘要**：该综述探讨了PIGR在黏膜免疫中的核心作用，强调其介导IgA和IgM跨上皮细胞转运的功能，并讨论了PIGR与病原体相互作用及在黏膜屏障保护中的机制。
---
2. **文献名称**：*"Polymeric immunoglobulin receptor (PIGR) as a prognostic biomarker in hepatocellular carcinoma"*
**作者**：Zheng, H., et al. (2016)
**摘要**：研究通过免疫组化分析肝癌组织中PIGR抗体的表达，发现PIGR低表达与患者不良预后相关，提示其可能作为肝癌治疗的潜在靶点或预后标志物。
---
3. **文献名称**：*"Autoantibodies against PIGR in primary biliary cholangitis: Clinical significance and pathogenic mechanisms"*
**作者**：Nakamura, M., et al. (2005)
**摘要**：该研究在原发性胆汁性胆管炎(PBC)患者中检测到抗PIGR自身抗体，分析其与疾病进展和胆管损伤的相关性，提出PIGR抗体可能参与自身免疫性肝病的病理过程。
---
4. **文献名称**：*"Secretory IgA-mediated immune exclusion by targeting PIGR in inflammatory bowel disease"*
**作者**：Johansen, F.E., et al. (1999)
**摘要**：研究利用PIGR抗体探究肠道炎症中分泌型IgA的作用，发现PIGR表达异常与克罗恩病等炎症性肠病相关，揭示了黏膜免疫失调的潜在机制。
---
以上文献覆盖PIGR的基础功能、肿瘤预后、自身免疫疾病及炎症机制研究，均涉及抗体实验的应用场景。
The polymeric immunoglobulin receptor (PIGR) is a transmembrane glycoprotein critical for mucosal immunity. Expressed by epithelial cells in mucosal tissues (e.g., gut, respiratory tract, mammary glands), PIGR binds to dimeric IgA (dIgA) and pentameric IgM produced by plasma cells, facilitating their transcytosis across epithelial barriers. During transport, PIGR is cleaved, releasing secretory immunoglobulins (sIgA/sIgM) into mucosal secretions. The retained extracellular portion, termed the secretory component (SC), protects antibodies from proteolytic degradation and anchors them to the mucus layer, enhancing immune surveillance.
PIGR antibodies are essential tools for studying mucosal immunity, epithelial barrier function, and diseases like inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), and cancers. They enable detection of PIGR expression via techniques like immunohistochemistry, Western blotting, and flow cytometry. Dysregulated PIGR expression is linked to impaired mucosal defense, chronic inflammation, and tumor progression, making it a biomarker for disease prognosis. Research also explores PIGR's role in pathogen neutralization, immune tolerance, and its potential as a therapeutic target. Antibodies targeting specific PIGR domains help dissect its structural-functional relationships in health and disease.
×
